# EDGAR Filing Document

**Accession Number:** 0001857948
**File Stem:** 0001857948-26-000003
**Filing Date:** 2026-3
**Character Count:** 8462
**Document Hash:** 6d68e1b570597fa55a95cc02a5996ca1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001857948-26-000003.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001857948-26-000003

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nautilus Biotechnology, Inc.
- **CENTRAL INDEX KEY:** 0001808805
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 981541723
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91615
- **FILM NUMBER:** 26723576

**BUSINESS ADDRESS:**
- **STREET 1:** 2701 EASTLAKE AVE EAST
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98102
- **BUSINESS PHONE:** 206-333-2001

**MAIL ADDRESS:**
- **STREET 1:** 2701 EASTLAKE AVE EAST
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ARYA Sciences Acquisition Corp III
- **DATE OF NAME CHANGE:** 20200408
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mallick Parag
- **CENTRAL INDEX KEY:** 0001857948

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** C/O NAUTILUS BIOTECHNOLOGY, INC.
- **STREET 2:** 201 INDUSTRIAL RD. #310
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Nautilus Biotechnology, Inc.**

*(Name of Issuer)*

**Common stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**63909J108**

*(CUSIP Number)*

**Parag Mallick**<br>2701 Eastlake Avenue East<br>Seattle WA 98102<br>206-333-2001

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/02/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **63909J108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Parag Mallick** | Name of reporting person<br>**Parag Mallick** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**22357411.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**200000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**22357411.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**200000.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**22557411.00** | Aggregate amount beneficially owned by each reporting person<br>**22557411.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.6%** | Percent of class represented by amount in Row (11)<br>**17.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Items 7, 9, and 11 above consists of 20,493,392 shares of Common Stock directly owned by Parag Mallick and a total of 1,864,019 shares of Common Stock issuable upon exercise of options. Of such options to purchase shares, 1,234,018 shares shall be vested and exercisable within 60 days of March 2, 2026.

Items 8, 10, and 11 above consists of 200,000 shares of Common Stock directly owned by The Dream Finder Foundation (the "Foundation"). Dr. Mallick and his spouse share voting and dispositive power over the shares held by the Foundation and Dr. Mallick is the President of the Foundation.

Item 13 above is based on the quotient obtained by dividing (a) the aggregate number of shares of Common Stock beneficially owned by Dr. Mallick by (b) the sum of (i) 126,564,473 shares of Common Stock outstanding as of February 19, 2026, as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission on February 26, 2026, and (ii) the 1,864,019 shares of Common Stock issuable upon exercise of options held by Dr. Mallick. The aggregate number of shares of Common Stock beneficially owned by Dr. Mallick as set forth in clauses "(a)" and "(b)" of this footnote are treated as outstanding shares of Common Stock only for the purpose of computing the percentage ownership of Dr. Mallick.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common stock, par value $0.0001 per share

**(b) Name of Issuer:**
Nautilus Biotechnology, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
2701 Eastlake Avenue East, Seattle, WA, 98102

This Amendment No. 2 (this "Amendment") amends and supplements the Schedule 13D filed on June 16, 2021, as amended by Amendment No. 1 filed on March 5, 2025 (the "Schedule 13D") by Parag Mallick (the "Reporting Person") relating to the Common Stock of Nautilus Biotechnology, Inc. (the "Issuer"). Information reported in the Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Schedule 13D. All references in the Schedule 13D and this Amendment shall be deemed to refer to the Schedule 13D as amended and supplemented by this Amendment.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date of this Schedule 13D, the Reporting Person beneficially owns an aggregate of 22,557,411 shares of Common Stock, or 17.6% of the Issuer's outstanding shares of Common Stock. The beneficial ownership percentages used in this Schedule are calculated based on a total of 126,564,473 shares of Common Stock outstanding as of February 19, 2026 plus 1,864,019 shares of Common Stock issuable upon exercise of options held by the Reporting Person.

1,234,018 of the Reporting Person's options to purchase shares of Common Stock are exercisable within 60 days of March 2, 2026. The unvested options to purchase shares of Common Stock vest over time subject to the Reporting Person's continued service through each vesting date. If, during the period beginning three months before a change in control through the one-year anniversary of a change in control, the Reporting Person's employment with the Issuer is terminated either (x) by the Issuer without cause, and excluding by reason of the Reporting Person's death or disability or (y) by the Reporting Person for good reason, then 100% of any unvested shares shall immediately vest.

**(b)**
The Reporting Person and the Reporting Person's spouse share voting and dispositive power with respect to 200,000 shares of Common Stock owned by the Foundation. The Reporting Person has sole voting and dispositive power with respect to 20,493,392 shares of Common Stock and options to purchase 1,864,019 shares of Common Stock.

**(c)**
On March 2, 2026, the Reporting Person was granted an option to purchase 280,000 shares of the Issuer's Common Stock. Except for such option grant, the Reporting Person has not effected any transactions in the Common Stock during the past 60 days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Parag Mallick

**Signature:** /s/ Matthew Murphy

**Name/Title:** Matthew Murphy/Attorney-in-fact

**Date:** 03/04/2026